MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qai.0000000000003392

Медицинская библиотека · Journal of acquired immune deficiency syndromes (1999) · 2024

Advanced HIV disease in East Africa and Nigeria, in The African Cohort Study.

Oboho Ikwo K, Esber Allahna L, Dear Nicole, Paulin Heather N, Iroezindu Michael, Bahemana Emmanuel, Kibuuka Hannah, Owuoth John, Maswai Jonah, Shah Neha, Crowell Trevor A, Ake Julie A, Polyak Christina S, AFRICOS Study Group

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

BACKGROUND

Earlier antiretroviral therapy (ART) may decrease progression to advanced HIV disease (AHD) with CD4 count of <200 cells per cubic millimeter or clinical sequelae. We assessed factors associated with AHD among people living with HIV before and during the "test and treat" era.

SETTING

The African Cohort Study prospectively enrolls adults with and without HIV from 12 clinics in Uganda, Kenya, Tanzania, and Nigeria.

METHODS

Enrollment evaluations included clinical history, physical examination, and laboratory testing. Generalized estimating equations were used to estimate adjusted odds ratios and 95% confidence intervals for factors associated with CD4 count of <200 cells per cubic millimeter at study visits.

RESULTS

From 2013 to 2021, 3059 people living with HIV with available CD4 at enrollment were included; median age was 38 years [interquartile range: 30-46 years], and 41.3% were men. From 2013 to 2021, the prevalence of CD4 count of <200 cells per cubic millimeter decreased from 10.5% to 3.1%, whereas the percentage on ART increased from 76.6% to 100% ( P <0.001). Factors associated with higher odds of CD4 count of <200 cells per cubic millimeter were male sex (adjusted odds ratio 1.56 [confidence interval: 1.29 to 1.89]), being 30-39 years (1.42 [1.11-1.82]) or older (compared with <30), have World Health Organization stage 2 disease (1.91 [1.48-2.49]) or higher (compared with stage 1), and HIV diagnosis eras 2013-2015 (2.19 [1.42-3.37]) or later (compared with <2006). Compared with ART-naive, unsuppressed participants, being viral load suppressed on ART, regardless of ART duration, was associated with lower odds of CD4 count of <200 cells per cubic millimeter (<6 months on ART: 0.45 [0.34-0.58]).

CONCLUSION

With ART scale-up, AHD has declined. Efforts targeting timely initiation of suppressive ART may further reduce AHD risk.

Для цитирования: Oboho Ikwo K, Esber Allahna L, Dear Nicole, Paulin Heather N, Iroezindu Michael, Bahemana Emmanuel, Kibuuka Hannah, Owuoth John, Maswai Jonah, Shah Neha, Crowell Trevor A, Ake Julie A, Polyak Christina S, AFRICOS Study Group. Advanced HIV disease in East Africa and Nigeria, in The African Cohort Study.. Journal of acquired immune deficiency syndromes (1999). 2024. DOI: 10.1097/qai.0000000000003392.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.